Page 12 - Pharma Industry

Zydus Lifesciences unit gets 10 observations from USFDA after inspection

Zydus Lifesciences on Wednesday said the US health regulator has issued ten observations after inspecting its injectable manufacturing plant near Vadodara in Gujarat. The US Food and Drug Administration (USFDA) inspected the facility at Jarod near Vadodara from April 15 to April 23, the drug maker said in a regulatory filing. The inspection closed with ten observations, it added. The company will closely work with the USFDA to address and respond to the observations in an expeditious manner, Zydus Lifesciences said. Shares of the company were trading 2.79 per cent down at Rs 932.80 apiece on the BSE.

Zydus Lifesciences gets China nod for drug to treat CKD-linked anaemia

It is estimated that more than 120 million people are living with chronic kidney disease in China

Anti-ageing tech, 'happiness medicines' to shape healthcare demand: Report

Wearables, anti-ageing hormone therapy, controlled psychedelics among 40 areas that will likely grow, it says

Result preview: Domestic biz, easing price pressure to boost pharma margins

Hospitals and Diagnostics revenues to grow 13-15% in Q4

Sanofi eyes speedy growth in India, plans fast-tracking of product pipeline

Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic drug firms, according to a top company official. The company plans to enhance its presence in the diabetes segment and grow its consumer healthcare business after spinning it off into a new entity while also looking at local production of its various best-in-class products in India. In an interaction with PTI, Sanofi India Managing Director Rodolfo Hrosz stated that the company has embarked on a mission to prepare for an accelerated growth path in the country. "We believe we're under-represented (in India) and we see a significant opportunity right now and in the future as well. The potential of this market is phenomenal," he said. He further said: "We are seeking the route to be better represented ... with a fair share of the Indian pharmaceutical ...

Ayurveda products market in India to reach Rs 1.2 trillion by FY28: Report

India's Ayurveda product market is projected to reach USD 16.27 billion or Rs 1.2 lakh crore by FY28 from USD 7 billion or Rs 57,450 crore at present, according to a study. Ayurveda product market has experienced significant growth due to rising demand for natural and herbal remedies in local and international markets, increase in ayurvedic medical practitioners, government initiatives, and emergence of new entrepreneurs, Ayurveda tech startup NirogStreet said. Citing a survey, NirogStreet said the Ayurveda product market in India is expected to grow significantly, with projections indicating a substantial increase in market value to Rs 1,20,660 crore (USD 16.27 billion) by FY28. According to NirogStreet survey, the overall market for Ayurveda products and services is expected to grow at a CAGR of 15 per cent from FY23 to FY28, with the product and service sectors growing at a CAGR of 16 per cent and 12.4 per cent, respectively. The survey also estimated the value of the country's

Aurobindo Pharma commissions 4 plants in Andhra including Pen-G facility

Aurobindo Pharma on Monday said it has commissioned four state-of-the-art manufacturing facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), Injectable products and Granulation, through its wholly owned subsidiaries. Penicillin-G (Pen-G) facility, located in a SEZ at Kakinada in Andhra Pradesh, has a production capacity of 15,000 tonne per annum and also 1.8 lakh tonne of gulcose, while 6-Amino Penicillanic Acid plant has a capacity to produce 3,600 tonne annually, the drug maker said in a press release. The Rs 2,400 crore Pen-G plant is expected to start trial production in April and commercial production in a couple of months and the ramping up of the production will happen during the second quarter of the current fiscal, a senior official of the city-based drug maker had earlier said. The plant was approved under the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/Drug Intermediates and Active .

PLI schemes attract over Rs 1.06 trn investment; pharma gets major chunk

Production-linked incentive (PLI) schemes for 14 sectors have attracted over Rs 1.06 lakh crore investments till December 2023 with pharma and solar modules accounting for nearly half of the total, according to government data. The response to the schemes was tepid in sectors like IT hardware, auto, and auto components, textiles, and ACC battery storage till December last year. The government in 2021 announced PLI schemes for 14 sectors such as telecommunication, white goods, textiles, manufacturing of medical devices, automobiles, speciality steel, food products, high-efficiency solar PV modules, advanced chemistry cell battery, drones, and pharma with an outlay of Rs 1.97 lakh crore. According to the data, pharmaceuticals and drugs sector attracted Rs 25,813 crore till December last year, exceeding the expected investments of Rs 17,275 crore. The major beneficiary in this sector include Dr Reddy's Laboratories, Cipla, Glenmark Pharma, Biocon and Wockhardt Ltd. As regards the hig

Alcobev industry seek clarity on brand extension vs surrogate ads

List of products sold under the same brand name as alcobev for the past three years, including details of states where they were marketed

IVI commences tech transfer of oral cholera vaccine to Biological E

The tech transfer will be completed by 2025 and the vaccine will be manufactured for India and international markets by Biological E

Unclear how many baby formula maker cases related to Enfamil: Reckitt

Shares of Reckitt, which owns brands such as Lysol, Dettol and Strepsils, that day suffered their steepest one-day drop since 1999, making it the top loser on London's blue-chip FTSE 100

Sun Pharma's growth pill: Specialising in specialty and scaling in India

Brokerages administer confidence boost, elevating EPS forecasts and target prices for 2024-25

Govt launches programme for cashless treatment of up to Rs 1.5 lakh

The government is launching a pilot programme to provide cashless treatment to road accident victims, under which they will be entitled to cashless treatment up to a maximum of Rs 1.5 lakh per accident, an official statement said on Thursday. The statement further said the pilot programme -- being initiated in Chandigarh and developed under the aegis of the Ministry of Road Transport and Highways (MoRTH) -- is aimed at establishing an ecosystem for providing timely medical care to the victims of road accidents, including during the golden hour. "The broad contours of the pilot programme are -- victims entitled to cashless treatment up to a maximum of Rs 1.5 lakh per accident per person for a maximum period of 7 days from date of the accident," it added. The statement said claims raised by hospitals for providing treatment will be reimbursed from the Motor Vehicle Accident Fund. According to the statement, the pilot project will be applicable to all road accidents caused by the use

Aurobindo Pharma to start production of Pen-G at its Andhra plant in Q1FY25

Aurobindo Pharma expects its Rs 2,400 crore Pen-G (penicillin) plant in Andhra Pradesh to start trial production in April and commercial production in a couple of months and ramping up of production will happen during the second quarter of next fiscal, a senior official of the city-based drug maker has said. Santhanam Subramanian, Chief Financial Officer of Aurobindo Pharma, also said the company is constructing a total of 10 new facilities which are expected to capitalise in the next one to two years. Currently, the firm has a total of 25 manufacturing and packaging facilities at various locations. The plant, which was approved under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country, will have a production capacity of around 15,000 tonnes annually. "We are doing the Pen-G project. We are in the process of installation and ...

Govt's new code bars unethical marketing of drugs by pharma firms

Medical representatives barred from using 'inducement' or 'subterfuge' to access healthcare professionals

Panel formed to administer pricing reforms for drugs, medical devices

Centre constitutes Committee for reforms in pricing framework for drugs and medical devices

Govt notifies new marketing code for pharma cos to curb unethical practices

The Department of Pharmaceuticals on Tuesday notified a new code which prohibits pharma companies from offering gifts and travel facilities to healthcare professionals or their family members. The Uniform Code for Pharmaceuticals Marketing Practices (UCPMP) 2024 also bans supply of free samples to those who are not qualified to prescribe such a product. "No gift should be offered or provided for personal benefit of any healthcare professional or family member (both immediate and extended) by any pharmaceutical company or its agent i.e. distributors, wholesalers, retailers, etc," as per the UCPMP guidelines. Similarly, no pecuniary advantage or benefit in kind may be offered, supplied, or promised to any person qualified to prescribe or supply drugs, by any pharmaceutical company or its agent i.e. distributors, wholesalers, retailers, etc, it added. Besides, the companies or their representatives, or any person acting on their behalf, should not extend travel facilities inside or ..

AstraZeneca, Mankind Pharma sign pact to distribute asthma medicine

AstraZeneca Pharma India Ltd and Mankind Pharma Ltd on Monday said they have entered into an agreement for exclusive distribution of the Symbicort brand, an asthma medicine, in India. Symbicort is owned by AstraZeneca, which will retain the intellectual property rights and will continue to be the marketing authorisation holder (MAH) and import license after the agreement, a joint statement shared on BSE by AstraZeneca Pharma India said. "The partnership with Mankind Pharma presents an opportunity to accelerate access and maximise the potential of our asthma drug as well as the turbuhaler which is a simple device, efficient in consistently delivering a higher proportion of respirable particles than the other devices," AstraZeneca India Managing Director and Country President Sanjeev Panchal said. Mankind Pharma has a distribution network, including close to 16,000 field forces and more than 13,000 stockists, across India providing access to quality pharmaceuticals across the country,

Hindustan Syringes launches Dispojekt to reduce needle stick injuries

Company aims to capture 60-70% of disposable syringes market in India

US FDA approves Eyenovia's eye drops to reduce pain: Formosa Pharma

Eyenovia acquired US commercial rights of the drug last August from Formosa